Evidence map›Paper›PMID 26010085›Full record

ArticlePloS one2015

Blood BDNF level is gender specific in severe depression.

Anatoly Kreinin, Serah Lisson, Elimelech Nesher, Jenny Schneider, Josef Bergman, Kamal Farhat, Joseph Farah, Flavio Lejbkowicz, Gal Yadid, Leon Raskin and 2 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Observational
  5. Gender Differences and Comorbidities in Major Depression.Advances in experimental medicine and biology · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anatoly KreininMaale HaCarmel Mental Health Center, Tirat HaCarmel, affiliated to Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel; Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Serah LissonDepartment of Molecular Biology, Ariel University, Ariel, Israel; Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.
Elimelech NesherDepartment of Molecular Biology, Ariel University, Ariel, Israel.
Jenny SchneiderDepartment of Molecular Biology, Ariel University, Ariel, Israel.
Josef BergmanMaale HaCarmel Mental Health Center, Tirat HaCarmel, affiliated to Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel; Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Kamal FarhatThe Nazareth Hospital, EMMS, affiliated with Faculty of Medicine, Bar Ilan University, Nazareth, Israel.
Joseph FarahThe Nazareth Hospital, EMMS, affiliated with Faculty of Medicine, Bar Ilan University, Nazareth, Israel.
Flavio LejbkowiczDepartment of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel; Clalit Health Services, National Cancer Control Center, Haifa, Israel.
Gal YadidFaculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.
Leon RaskinDivision of Epidemiology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, United States of America.
Igor KomanDepartment of Molecular Biology, Ariel University, Ariel, Israel.
Albert PinhasovDepartment of Molecular Biology, Ariel University, Ariel, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Though the role of brain derived neurotrophic factor (BDNF) as a marker for major depressive disorder (MDD) and antidepressant efficacy has been widely studied, the role of BDNF in distinct groups of patients remains unclear. We evaluated the diagnostic value of BDNF as a marker of disease severity measured by HAM-D scores and antidepressants efficacy among MDD patients. Fifty-one patients who met DSM-IV criteria for MDD and were prescribed antidepressants and 38 controls participated in this study. BDNF in serum was measured at baseline, 1st, 2nd and 8th treatment weeks. Depression severity was evaluated using the Hamilton Rating Scale for Depression (HAM-D). BDNF polymorphism rs6265 (val66met) was genotyped. We found a positive correlation between blood BDNF levels and severity of depression only among untreated women with severe MDD (HAM-D>24). Serum BDNF levels were lower in untreated MDD patients compared to control group. Antidepressants increased serum BDNF levels and reduced between-group differences after two weeks of treatment. No correlations were observed between BDNF polymorphism, depression severity, duration of illness, age and BDNF serum levels. Further supporting the role of BDNF in the pathology and treatment of MDD, we suggest that it should not be used as a universal biomarker for diagnosis of MDD in the general population. However, it has diagnostic value for the assessment of disease progression and treatment efficacy in individual patients.

Indexed as

Sex CharacteristicsAdultBrain-Derived Neurotrophic FactorCase-Control StudiesDemographyFemaleGenotypeHumansMajor Depressive DisorderMaleMiddle AgedBDNF protein, humanBrain-Derived Neurotrophic Factor

Identifiers

PMID26010085
PMCPMC4444333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.